Request Demo
Last update 24 Oct 2025
SGB-9768
Last update 24 Oct 2025
Overview
Basic Info
Drug Type siRNA |
Synonyms SGB 9768, SGB9768 |
Target |
Action inhibitors |
Mechanism C3 inhibitors(Complement C3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Login to view timeline
Structure/Sequence
Boost your research with our RNA technology data.
login
or
Related
4
Clinical Trials associated with SGB-9768NCT06786338
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of SGB-9768 in Patients with Primary IgA Nephropathy, C3 Glomerulopathy, and Immune Complex-mediated Membranoproliferative Glomerulonephritis.
ChiCTR2500098240
A multi-center, open-label, Phase II study to evaluate the efficacy and safety of SGB-9768 in patients with primary IgAropathy, C3 glomerulopathy, and immune complex-mediated membranoproliferative glomerulonephritis.
NCT06501573
A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-9768 in Healthy Volunteers
100 Clinical Results associated with SGB-9768
Login to view more data
100 Translational Medicine associated with SGB-9768
Login to view more data
100 Patents (Medical) associated with SGB-9768
Login to view more data
100 Deals associated with SGB-9768
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| C3 glomerulopathy | Phase 2 | China | 01 Apr 2025 | |
| Glomerulonephritis, IGA | Phase 2 | China | 01 Apr 2025 | |
| Glomerulonephritis, Membranoproliferative | Phase 2 | China | 01 Apr 2025 | |
| Immune System Diseases | IND Approval | New Zealand | 27 Feb 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT06501573 (NEWS) Manual  | Phase 1 | - | 55 | eukuekglvx(igtjosdjha) = SGB-9768表现出良好的安全性和耐受性。 dcixeizsve (ylwdqdtpeb ) View more | Positive | 11 Dec 2024 | |
Placebo |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free